Most Read Articles
21 Dec 2019
There remains no single, convenient tool available for use as a gold standard in evaluation of quality of life in pruritus, a new study has shown.
Roshini Claire Anthony, 22 Jan 2020

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.

Crisaborole suppresses skin inflammation in atopic dermatitis

15 Nov 2019

Crisaborole treats atopic dermatitis (AD) by suppressing skin inflammation and improving barrier function, a recent study has found.

Forty adults (mean age, 32.2 years; 27 women) with mild-to-moderate AD were randomly allocated, on a 1:1 basis, to the crisaborole or vehicle control group for 14 days. This was followed by a 28-day open-label phase where crisaborole was given to all participants to apply to all affected areas. Punch biopsies were collected at days 8 and 15 for biomarker analysis.

Lesional total sign score showed a greater 15-day change for lesions that were treated with crisaborole than with the vehicle control (–4.5 vs –2.1 points; p<0.0001). This effect was present as early as day 8 (–3.3 vs –1.2 points; p<0.0001).

Similarly, better pruritus numerical rating scale scores were reported for the crisaborole-treated lesions. This was evident starting from the first day after treatment initiation and remained consistent until the 15-day follow-up.

These clinical benefits could be explained by the molecular changes that crisaborole effected. Compared with vehicle-treated lesions, the mRNA expression profiles of inflammatory mediator genes were significantly improved in areas treated with crisaborole. This included the suppression of key AD-related genes and enrichment of negative regulators.

“Moreover, only crisaborole-treated lesions showed a reversal in molecular dysregulation, approaching the nonlesional skin profile at both time points for the entire study population and for each patient,” said researchers, pointing out that changes in vehicle-treated regions were more modest and could be explained off as potential effects of the ointment base.

Editor's Recommendations
Most Read Articles
21 Dec 2019
There remains no single, convenient tool available for use as a gold standard in evaluation of quality of life in pruritus, a new study has shown.
Roshini Claire Anthony, 22 Jan 2020

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.